Please login to the form below

Not currently logged in
Email:
Password:

NICE turns down Opdivo but offers CDF hope

Wants more cost-effectiveness data to be gathered

BMSThe UK's National Institute for Health and Care Excellence has again not recommended Bristol-Myers Squibb's lung cancer immunotherapy Opdivo for use on the NHS.

 But the cost-effectiveness body has offered the company the opportunity for a limited trial through the newly-reformed Cancer Drugs Fund.

 Concluding a year-long discussion with BMS and NHS England, NICE said in draft guidance that Opdivo (nivolumab) is not cost-effective for all patients with squamous and non-squamous advanced non-small cell lung cancer (NSCLC).

 The watchdog has, however, acknowledged a particular benefit in NSCLC patients with PD-L1 status and has requested that BMS prepare its case for the inclusion of Opdivo in the CDF to gather more information on its cost-effectiveness in this patient population.

 Commenting on the decision, Benjamin Hickey, general manager of BMS UK & Ireland, said that the firm is "extremely disappointed for the majority of lung cancer patients for whom this NICE guidance could deny a potential life-line".

 He added: "We strongly disagree with the notion that nivolumab treatment should be restricted to around one third of patients because this is inconsistent with the clinical evidence."

 A PD-1 inhibitor, Opdivo targets PD-L1 proteins on the surface of cells, which are responsible for reducing the effectiveness of immune cells. Cancerous lung cells have more PD-L1 than normal cells, preventing the body from attacking the tumour.

Data from the CheckMate-057 clinical trials showed that Opdivo extended the survival period for NSCLC patients with PD-L1 status by seven months more than those with less PD-L1, but overall, 39% of Opdivo-treated patients were still alive after 18 months compared with just 23% of patients treated with the standard Taxoterre (doxetaxel) chemotherapy.

However, at a minimum of £73,500 per quality-adjusted life year (QALY) for squamous NSCLC and over £150,000 per QALY for non-squamous NSCLC, the cost of the drug far exceeds the usual incremental cost-effectiveness ratio (ICER) sought by NICE.

Hickey added: "We continue to be open to finding a solution for all advanced lung cancer patients who could potentially benefit from nivolumab."

Article by
Rebecca Clifford

14th October 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics